Sirnaomics
Sirnaomics is a leading biopharmaceutical company focused on discovery and development of RNAi therapeutics for cancer, fibrotic diseases, and other high unmet medical needs. With a strong portfolio of intellectual property and a broad pipeline, the company leverages innovative RNA interference technology, delivery platforms, and a global vision to develop novel therapeutics aimed at alleviating human suffering and advancing patient care.
Industries
Nr. of Employees
medium (51-250)
Sirnaomics
Patents
Composition and methods of RNAi prophylactics and therapeutics for treatment of severe acute respiratory infection caused by 2019 novel coronavirus (2019-nCoV)
US-12006500-B2
View DetailsPharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis
US-11697813-B2
View DetailsSirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection
US-11058779-B2
View DetailsCompositions and methods for “resistance-proof” SiRNA therapeutics for influenza
US-9868952-B2
View Details
Composition and methods of RNAi prophylactics and therapeutics for treatment of severe acute respiratory infection caused by 2019 novel coronavirus (2019-nCoV)
US-12006500-B2
View DetailsPharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis
US-11697813-B2
View DetailsSirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection
US-11058779-B2
View DetailsCompositions and methods for “resistance-proof” SiRNA therapeutics for influenza
US-9868952-B2
View DetailsProducts
Dual‑targeting siRNA therapeutic for cutaneous and fibrotic indications (lead clinical candidate)
siRNA candidate designed to simultaneously reduce expression of two pro‑fibrotic/pro‑tumorigenic genes; formulated for intralesional and systemic administration and progressed through Phase I/II clinical studies.
Systemic siRNA therapeutic candidate for solid tumors (IV formulation)
Systemically administered siRNA candidate formulated with peptide copolymer carriers for intravenous delivery to solid tumors; evaluated in preclinical models and advanced into Phase I studies.
GalNAc-based liver‑targeted siRNA programs
Liver‑directed siRNA development programs using GalNAc conjugation for targeted hepatocyte delivery, applied to cardiovascular and coagulation indications in clinical studies.
mRNA vaccine and therapeutic candidates using PLNP and AI design
mRNA vaccine and therapeutic development combining polypeptide‑lipid nanoparticle delivery and AI epitope prediction methods to select antigens and design mRNA constructs.
Dual‑targeting siRNA therapeutic for cutaneous and fibrotic indications (lead clinical candidate)
siRNA candidate designed to simultaneously reduce expression of two pro‑fibrotic/pro‑tumorigenic genes; formulated for intralesional and systemic administration and progressed through Phase I/II clinical studies.
Systemic siRNA therapeutic candidate for solid tumors (IV formulation)
Systemically administered siRNA candidate formulated with peptide copolymer carriers for intravenous delivery to solid tumors; evaluated in preclinical models and advanced into Phase I studies.
GalNAc-based liver‑targeted siRNA programs
Liver‑directed siRNA development programs using GalNAc conjugation for targeted hepatocyte delivery, applied to cardiovascular and coagulation indications in clinical studies.
mRNA vaccine and therapeutic candidates using PLNP and AI design
mRNA vaccine and therapeutic development combining polypeptide‑lipid nanoparticle delivery and AI epitope prediction methods to select antigens and design mRNA constructs.
Services
Design and conduct of early-phase clinical trials (IND filings, Phase I/II designs, dose escalation/expansion, intralesional and IV administration).
Licensing of nanoparticle delivery platforms (polypeptide and polypeptide‑lipid systems) and transfer of related formulation know‑how.
In vivo efficacy testing in rodent xenograft and disease models and safety studies including non‑human primates to support IND submissions.
Guidance and execution for scalable GMP manufacturing of oligonucleotide and nanoparticle formulations for clinical supply.
Design and conduct of early-phase clinical trials (IND filings, Phase I/II designs, dose escalation/expansion, intralesional and IV administration).
Licensing of nanoparticle delivery platforms (polypeptide and polypeptide‑lipid systems) and transfer of related formulation know‑how.
In vivo efficacy testing in rodent xenograft and disease models and safety studies including non‑human primates to support IND submissions.
Guidance and execution for scalable GMP manufacturing of oligonucleotide and nanoparticle formulations for clinical supply.
Expertise Areas
- RNAi therapeutic discovery and development
- Oligonucleotide delivery platform development
- Preclinical in vivo efficacy and IND‑enabling studies
- Clinical trial design and early‑phase execution
Key Technologies
- RNA interference (siRNA)
- Polypeptide nanoparticle delivery
- Histidine‑lysine copolymer peptide carriers
- GalNAc liver‑targeting chemistry
News & Updates
Sirnaomics announced that its management will present and conduct face-to-face meetings at the 2019 BIO CEO & Investor Conference in New York, NY on February 11-12, 2019. Patrick Y. Lu, PhD, Founder and CEO, will present an overview of the company's RNAi technology platform and clinical pipeline.
Sirnaomics announced that its management will present and conduct face-to-face meetings at the 2019 BIO CEO & Investor Conference in New York, NY on February 11-12, 2019. Patrick Y. Lu, PhD, Founder and CEO, will present an overview of the company's RNAi technology platform and clinical pipeline.